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Abstract
Objective: To investigate whether the burden of white matter hyperintensities
(WMHs) is associated with the risk of developing levodopa-induced dyskinesia
(LID) in Parkinson’s disease (PD). Methods: According to the Clinical Research
Center for Dementia of South Korea WMH visual rating scale, 336 patients
with drug-na€ıve early stage PD (follow-up >3 years) were divided into two
groups of PD with minimal WMHs (PD-WMH–; n = 227) and moderate-to-
severe WMHs (PD-WMH+; n = 109). The Cox regression model was used to
estimate the hazard ratio for the development of LID in the PD-WMH + group
compared with the PD-WMH– group, while adjusting for age at PD onset, sex,
striatal dopamine depletion, and PD medication dose. Additionally, we assessed
the effects of WMH burden rated by the Scheltens scale and regional WMH
distribution on the development of LID. Results: Patients in the PD-
WMH + group were older and had more severe parkinsonian motor signs
despite comparable striatal dopamine transporter availability than those in the
PD-WMH– group. Patients in the PD-WMH + group had a higher risk of
developing LID (hazard ratio, 2.66; P < 0.001) than those in the PD-WMH–
group after adjustment for other confounding factors. A greater WMH burden
was associated with earlier occurrence of LID (hazard ratio, 1.04; P = 0.001),
although the effects of WMHs on LID development did not exhibit region-
specific patterns. Interpretation: The present study demonstrates that the bur-
den of WMHs is associated with occurrence of LID in patients with PD, sug-
gesting comorbid WMHs as a risk factor for LID.
Introduction
Levodopa-induced dyskinesia (LID) occurs within several
years in most patients with Parkinson’s disease (PD) who
have undergone chronic dopamine replacement therapy,1
although the timing of the development of LID varies
among patients. The pathogenesis underlying LID consists
of two major events2,3: loss of nigral dopaminergic neu-
rons with an impaired capacity for striatal dopamine stor-
age and plastic alterations of the basal ganglia structures
in response to pulsatile stimulations with exogenous
dopamine. Additionally, it has been widely gaining accep-
tance that both presynaptic and postsynaptic mechanisms
are likely to result in aberrant plasticity in motor
networks (i.e., striato-cortical, cortico-cortical, and cere-
bello-cortical connections),4 which is also associated with
the early development of LID.5–7
White matter hyperintensities (WMHs) are commonly
observed in approximately 30–50% of patients with PD,8,9
and several studies have demonstrated that a greater
WMH burden is associated with severe motor impair-
ments, especially axial motor symptoms, in PD.10–12
However, these previous studies were essentially cross-sec-
tional, and the effects of WMHs on long-term motor out-
comes, including the development of LID, have not yet
been reported. Given that WM alterations may disconnect
the motor cortex from the basal ganglia and cerebellum13
and even exert actions outside the visible lesions by
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remote effects,14,15 we hypothesized that an increased
WMH burden would be associated with a higher risk of
LID in patients with PD. To test this, we investigated the
occurrence of LID in 336 patients with de novo PD
according to the severity of WMHs during a follow-up
period of approximately 5.5 years. In addition, we evalu-
ated whether the impact of WMHs on the development
of LID would depend on regional WMH distribution.
Methods
Subjects
We retrospectively reviewed the medical records of 484
consecutive patients with drug-na€ıve early stage PD who
visited the movement disorders outpatient clinic at Sever-
ance Hospital between April 2009 and September 2015.
Of these, 148 patients were lost to follow-up within
3 years and were excluded from the study. A total of 336
patients were treated with PD medications for at least
3 years, with doses adjusted for effective symptom control
according to the patient’s response. PD was diagnosed
according to the clinical diagnostic criteria of the United
Kingdom Parkinson’s disease Society Brain Bank. All sub-
jects underwent brain magnetic resonance imaging (MRI)
scans at initial assessment, including fluid-attenuated
inversion recovery (FLAIR) sequence images, and 18F-N-
(3-fluoropropyl)-2b-carbon ethoxy-3b-(4-iodophenyl)
nortropane (18F-FP-CIT) positron emission tomography
(PET). Parkinsonian motor symptoms were assessed using
the Unified Parkinson’s Disease Rating Scale Part III
(UPDRS-III). PD medication doses were calculated as
levodopa-equivalent doses (LEDs).16 This study was
approved by the Yonsei University Severance Hospital
institutional review board, and the need for informed
consent was waived because of the retrospective nature of
the study.
Rating of the WMH burden in patients with
PD
Acquisition of FLAIR sequence images
Of the 336 patients with PD, 277 (82.4%) patients under-
went brain MRI scans at Severance Hospital using a 3.0 T
scanner (Achieva; Philips Medical System, Best, The
Netherlands). The FLAIR sequence images were acquired
with the following parameters: matrix, 512 9 512; slice
number, 22; pixel spacing, 0.449 9 0.449 mm2; slice
thickness, 5 mm; gap, 2 mm; field of view, 230 mm; rep-
etition time, 11,000 msec; echo time, 125 msec; inversion
time, 2,800 msec; flip angle, 90°. The other 59 (17.6%)
patients underwent brain MRI scans including FLAIR
sequence images at other hospitals before being referred
to our hospital.
Classification of patients with PD according to the
severity of WMHs
The WMH burden of all 336 patients with de novo PD was
rated on FLAIR images using the Clinical Research Center
for Dementia of South Korea (CREDOS) WMH visual rat-
ing scale, which correlated well with the automatically mea-
sured WMH volume in a previous work.17,18 First, the
modified Fazekas scale was used to describe the extent of
periventricular and deep WMHs.19 Hyperintensities evident
in the axial slice just above the top of the lateral ventricles
were considered to be periventricular WMH, whereas hyper-
intensities evident in the second or more axial slices above
the top of the lateral ventricles were considered to be deep
WMH.17 Periventricular WMHs were classified as P1 (cap
and band <5 mm), P2 (between P1 and P3), or P3 (10 mm
≤cap or band) based on the size of cap and band, which
were perpendicular and horizontal to the ventricle, respec-
tively. Deep WMH were classified as D1 (maximum diame-
ter of deep white matter lesion <10 mm), D2 (10 mm
≤lesion <25 mm), or D3 (lesion ≥25 mm) based on the
longest diameter of the white matter lesions (see Fig. 1).
Then, we divided the patients into two groups according to
the CREDOS ischemia classification system: a PD group
with minimal WMHs (D1P1 and D1P2; PD-WMH–;
n = 227) and a PD group with moderate-to-severe WMHs
(D1P3, D2P1, D2P2, D2P3, D3P1, D3P2, and D3P3; PD-
WMH+, n = 109). WMH ratings were performed by two
neurologists (LYH and YHS) blinded to the clinical infor-
mation. The inter-rater reliability for ratings of periventricu-
lar WMH and deep WMH was excellent (j = 0.887 and
0.899, respectively), and the raters reached a consensus in
cases of discrepancy.
A semi-quantitative rating of WMHs using the
Scheltens scale
Additionally, two neurologists (LYH and YHS) assessed
the WMH burden of each patient using the Scheltens
scale in which periventricular and lobar (frontal, parietal,
temporal, and occipital) WMHs, as well as basal ganglia
and infratentorial signal hyperintensities were rated sepa-
rately in a semi-quantitative manner.20 A final consensus
rating between the two raters was used for the analysis.
Quantitative analyses of the 18F-FP-CIT PET
images
We used the same methodology to obtain and analyze the
18F-FP-CIT PET data to calculate the dopamine
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transporter (DAT) availability in the posterior putamen
as previously described (see Data S1).21
Assessment of the development of LID in
the PD groups
After the diagnosis of PD, patients visited our outpatient
clinic at 3- to 4-month intervals, and two movement dis-
order specialists (SYH and LPH) assessed the presence of
LID at every visit (average number of visits, 20.20  6.37
times). The time from treatment initiation to the onset of
LID was assessed with Kaplan–Meier estimates in the 109
patients with moderate-to-severe WMHs and the 227
patients with minimal WMHs. A log-rank test was used
to compare the Kaplan–Meier plots between the PD
groups. To assess the effect of WMHs on the develop-
ment of LID, the Cox regression model was used to esti-
mate hazard ratios (HR) and 95% confidence intervals
(CI) while adjusting for age at PD onset, sex, DAT avail-
ability in the posterior putamen, and LED per body
weight at LID onset in patients with dyskinesia or at the
last visit to the outpatient clinic in those without
dyskinesia.
Additionally, to reduce the effects of potential con-
founding factors and provide the covariate balance,
propensity scores were used to match the PD-
WMH + group with a subset of the PD-WMH–
group. The propensity score for the predicted proba-
bility of the severity of WMHs in each patient was
estimated using a logistic regression model including
the patient’s age at parkinsonian symptom onset, sex,
PD duration, UPDRS-III scores, and DAT availability
in the posterior putamen as variables. Then, we cre-
ated a propensity score-matched cohort by matching
each subject with moderate-to-severe WMHs to one
subject with minimal WMHs (a 1:1 match). The
propensity score matching was performed with the R
software package, version 3.4.0 (http://www.r-project.
org). Sensitivity analyses were then performed in
these matched samples (i.e., the 109 patients in the
PD-WMH + group and the matched 109 patients in
the PD-WMH– group; see Data S1).
Figure 1. Examples of cases rated as P1, P2, P3, and D1, D2, D3.
ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 231
S. J. Chung et al. WMH and LID in PD
Assessment of the development of LID
according to the regional WMH burden
Cox regression analysis was performed to assess the effect
of the regional WMH burden rated by the Scheltens
scale20 on the development of LID, while adjusting for
age at PD onset, sex, DAT availability in the posterior
putamen, and LED per body weight. In addition, to
demonstrate which regional WMHs (i.e., periventricular,
lobar [frontal, parietal, temporal, and occipital], basal
ganglia, and infratentorial WMHs) is more explanatory
and informative in predicting the development of LID,
the following parameters were calculated for each Cox
regression model: the Akaike information criterion (AIC),
the discriminatory ability assessed by the linear trend chi-
squared test, the concordance index (Harrell’s C-index),
and a global concordance probability (integrated area
under the curve [iAUC]). A smaller AIC and larger dis-
criminatory ability, Harrell’s C-index, and iAUC indicate
the preferred model with better predictive accuracy. We
also compared the iAUC between the Cox regression
models using a bootstrapping method with resampling
1000 times.
Statistical analyses
The baseline demographic characteristics, WMHs rated by
the Scheltens scale, and the striatal DAT availability of the
PD groups were compared with Student’s t-tests and
Pearson’s chi-squared tests. The effect of WMHs on the
development of LID was assessed with a log-rank test and
the Cox regression model as described above. Pearson’s
correlation coefficients were calculated to assess the corre-
lation between the WMH rating scores in each brain
region. The statistical analyses were performed with SPSS
(version 23.0; IBM Corporation, Armonk, NY, USA), and
results with a two-tailed p-value < 0.05 were considered
statistically significant.
Results
Baseline clinical characteristics of the
patients with PD
Baseline demographic characteristic and clinical features
are listed in Table 1. The patients in the PD-
WMH + group (n = 109) were older and had higher
Table 1. Baseline demographic characteristics in patients with PD.
Overall series Propensity score-matched pairs1
PD-WMH- (n = 227) PD-WMH+ (n = 109) P-value PD-WMH- (n = 109) PD-WMH+ (n = 109) P-value
Demographic characteristics
Age (years) 63.92  9.59 70.14  7.82 <0.001 69.49  8.39 70.14  7.82 0.553
Female, No. (%) 113 (49.5%) 56 (51.4%) 0.784 51 (46.8%) 56 (51.4%) 0.498
Onset of age (years) 62.45  9.74 68.68  7.85 <0.001 68.08  8.46 68.68  7.85 0.590
PD duration (months) 17.43  14.71 17.60  16.23 0.926 16.88  14.18 17.60  16.23 0.729
UPDRS-III 21.45  9.06 26.30  10.12 <0.001 24.17  8.73 26.30  10.12 0.098
Vascular risk factors
Hypertension 74 (32.6%) 58 (53.2%) <0.001 45 (41.3%) 58 (53.2%) 0.078
Diabetes mellitus 28 (12.3%) 26 (23.9%) 0.007 17 (15.6%) 26 (23.9%) 0.126
Dyslipidemia 32 (14.1%) 22 (20.2%) 0.155 17 (15.6%) 22 (20.2%) 0.377
Body mass index 23.52  2.99 23.17  3.25 0.334 23.52  3.04 23.17  3.25 0.410
LID occurrence, No. (%) 58 (25.6%) 43 (39.4%) 0.009 24 (22.0%) 43 (39.4%) 0.005
WMH burden2
Periventricular WMHs 1.77  1.12 4.27  1.27 <0.001 2.08  1.19 4.27  1.27 <0.001
Lobar WMHs 3.89  3.01 12.13  3.78 <0.001 4.45  3.24 12.13  3.78 <0.001
Basal ganglia WMHs 0.48  0.98 2.84  2.94 <0.001 0.61  1.11 2.84  2.94 <0.001
Infratentorial WMHs 0.36  0.83 0.95  1.33 <0.001 0.43  0.97 0.95  1.33 <0.001
Total WMHs 6.40  4.16 20.06  6.79 <0.001 7.50  4.45 20.06  6.79 <0.001
DAT availability
Posterior putamen 1.35  0.42 1.31  0.45 0.181 1.27  0.38 1.31  0.45 0.536
Values are expressed as mean  standard deviation or number (percentage). Abbreviations: PD, Parkinson’s disease; PD-WMH-, PD group with
minimal white matter hyperintensities (WMHs); PD-WMH+, PD group with moderate-to-severe WMHs; UPDRS-III, the Unified Parkinson’s Disease
Rating Scale Part III; LID, levodopa-induced dyskinesia; DAT, dopamine transporter.
1Propensity score matching using a logistic regression model including the age at onset, sex, PD duration, UPDRS-III scores, and DAT availability in
the posterior putamen as predictors.
2Based on the Scheltens scale (Journal of the Neurological Sciences 1993;114:7–12).
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UPDRS-III scores and a higher prevalence of hypertension
and diabetes mellitus than those in the PD-WMH– group
(n = 227). There were no significant differences in sex,
PD duration, and motor subtypes between the PD groups.
The PD-WMH + group showed a greater WMH burden,
as rated by the Scheltens scale20, in the periventricular,
lobar, basal ganglia, and infratentorial regions than the
PD-WMH– group. DAT availability in the posterior
putamen was comparable between the PD-WMH + group
(1.31  0.45) and PD-WMH– group (1.35  0.42;
P = 0.181).
Propensity score subsamples (109 in the PD-
WMH + group and 109 matched samples in the PD-
WMH– group) revealed no significant differences in base-
line demographic characteristics and striatal DAT avail-
ability between the PD groups, although the PD-
Figure 2. Curves of Kaplan–Meier estimates of the onset of levodopa-induced dyskinesia (LID) after treatment initiation in patients with
moderate-to-severe WMHs and matched patients with minimal WMHs. (A) Overall series. (B) Propensity score-matched pairs. The PD-
WMH + group had a higher risk of early development of LID than the PD-WMH– group (Plog-rank < 0.001). The crosses in the graphs indicate
censored data. Abbreviations: PD-WMH–, PD group with minimal white matter hyperintensities; PD-WMH+, PD group with moderate-to-severe
white matter hyperintensities.
Table 2. Cox regression analysis for the development of levodopa-induced dyskinesia in Parkinson’s disease groups according to white matter
hyperintensities.
Factors
Overall series Propensity score-matched pairs1
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Group (PD-WMH + vs. PD-WMH-) 2.660 (1.7424.062) <0.001 2.429 (1.459–4.042) 0.001
Age at PD onset 0.973 (0.953–0.994) 0.014 0.979 (0.951–1.008) 0.149
Sex (Female vs. Male) 1.718 (1.143–2.581) 0.009 1.886 (1.144–3.109) 0.013
DAT availability in posterior putamen 0.592 (0.373–0.941) 0.027 0.583 (0.328–1.036) 0.066
LED per body weight 1.005 (0.982–1.028) 0.670 1.017 (0.963–1.074) 0.547
Abbreviations: PD, Parkinson’s disease; PD-WMH+, PD group with moderate-to-severe white matter hyperintensities; PD-WMH-, PD group with
minimal white matter hyperintensities; DAT, dopamine transporter; LED, levodopa-equivalent; CI, confidence interval.
1Propensity score matching using a logistic regression model including the age at onset, sex, PD duration, UPDRS-III scores, and DAT availability in
the posterior putamen as predictors.
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WMH + group tended to have higher UPDRS-III scores
(P = 0.098) and a higher prevalence of hypertension
(P = 0.078) than the matched PD-WMH– group. The
PD-WMH + group exhibited a greater WMH burden
based on the Scheltens scale20 than the matched PD-
WMH– group (Table 1).
Development of LID in the PD groups
according to WMH severity
During the follow-up period, LID developed in 43 (39.4%)
of the 109 patients in the PD-WMH + group (follow-up
duration, 5.43  1.66 years) and in 58 (25.6%) of the 227
patients in the PD-WMH– group (follow-up duration,
5.99  1.87 years). The Kaplan–Meier analyses revealed that
the PD-WMH + group had a higher risk of developing LID
than the PD-WMH– group (Plog-rank <0.001; Fig. 2A). The
HR for developing LID after starting PD medication in the
PD-WMH + group compared with the PD-WMH– group
was 2.660 (95% CI [1.742  4.062]; p < 0.001), indicating
that the PD-WMH + group had a higher risk of developing
LID than the PD-WMH– group when the model was
adjusted for age at PD onset, sex, baseline striatal dopamine
depletion, and LED per body weight. In addition, older age
at onset, male sex, and mildly decreased DAT availability in
the posterior putamen were associated with a lower risk of
developing LID (Table 2).
We also obtained consistent results in propensity score
subsamples: The PD-WMH + group had a higher risk of
developing LID than the matched PD-WMH– group
(Plog-rank <0.001, Fig. 2B; HR 2.429, 95% CI
[1.459  4.042], P = 0.001, Table 2).
Development of LID according to the
regional WMH burden
The Cox regression model demonstrated that a greater
total WMH burden based on the Scheltens scale was
associated with a higher risk of developing LID in either
overall samples (HR, 1.044; 95% CI, [1.018  1.071];
P = 0.001) or propensity score subsamples (HR, 1.040;
95% CI, [1.012  1.069]; P = 0.005). Younger age at
onset, female sex, and severely decreased DAT availability
in the posterior putamen were also associated with a
higher risk of developing LID (Table 3).
Moreover, we investigated whether the impact of
WMHs on the development of LID would depend on the
regional WMH distribution. The Cox regression models
demonstrated that periventricular (HR, 1.139; 95% CI
[0.998  1.300]; P = 0.053), lobar (HR, 1.067; 95% CI
[1.025  1.110]; P = 0.002), basal ganglia (HR, 1.132;
95% CI [1.034  1.239]; P = 0.007), and infratentorial
(HR, 1.216; 95% CI [1.022  1.445]; P = 0.027) WMHs
were significantly associated with LID occurrence
(Table S1). In addition, WMH burden in the frontal
(HR, 1.196; 95% CI [1.047  1.366]; P = 0.008), parietal
(HR, 1.214; 95% CI [1.073  1.373]; P = 0.002), tempo-
ral (HR, 1.187; 95% CI [1.026  1.372]; P = 0.021), and
occipital (HR, 1.261; 95% CI [1.081  1.470]; P = 0.003)
lobes significantly affected the occurrence of LID
(Table S2). The predictive ability of each Cox regression
model was comparable in terms of the AIC, discrimina-
tory ability, and Harrell’s C-index (Table 4). In particular,
there were no significant differences in the iAUC between
the Cox regression models, which were calculated using a
bootstrapping method with resampling 1000 times. In
correlation analyses, there was a strong correlation
between WMH rating scores in each brain region with a
sufficiently large effect size (correlation coefficients >0.5;
Table S3).
Discussion
This study investigated the effects of baseline WMH bur-
den on the development of LID in patients with drug-
na€ıve early stage PD. The major findings were as follows:
Table 3. Cox regression analysis for the development of levodopa-induced dyskinesia according to white matter hyperintensities assessed by the
Scheltens scale.
Factors
Overall series Propensity score-matched pairs1
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Total WMHs 1.044 (1.018–1.071) 0.001 1.040 (1.012–1.069) 0.005
Age at PD onset 0.971 (0.949–0.994) 0.013 0.968 (0.940–0.998) 0.037
Sex (Female vs. Male) 1.594 (1.060–2.396) 0.025 1.718 (1.042–2.830) 0.034
DAT availability in posterior putamen 0.545 (0.336–0.882) 0.014 0.548 (0.300–1.001) 0.050
LED per body weight 1.006 (0.985–1.028) 0.566 1.030 (0.977–1.087) 0.273
Abbreviations: WMHs, white matter hyperintensities; PD, Parkinson’s disease; DAT, dopamine transporter; LED, levodopa-equivalent; CI, confi-
dence interval.
1Propensity score matching using a logistic regression model including the age at onset, sex, PD duration, UPDRS-III scores, and DAT availability in
the posterior putamen as predictors.
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(1) patients with PD with moderate-to-severe WMHs
were older and had higher UPDRS-III scores than those
with minimal WMHs. (2) Patients in the PD group with
moderate-to-severe WMHs had a higher risk of develop-
ing LID than those in the PD group with minimal
WMHs, after adjustment for confounding factors such as
age at onset, sex, striatal DAT availability, and doses of
PD medications. (3) A greater WMH burden was associ-
ated with an earlier occurrence of LID, although the
effects of WMHs on the development of LID were not
regionally dependent. These findings suggest that baseline
WMHs can act as a predictive marker or therapeutic tar-
get for the development of LID in patients with early
stage PD.
The underlying mechanisms of LID have traditionally
been described at the presynaptic and postsynaptic
levels.2,3 Presynaptic mechanisms refer to an impaired
regulation of the striatal synaptic dopamine level as a
consequence of the loss of nigral dopaminergic neurons
and hyperinnervation of serotonergic fibers.22 Postsynap-
tically, intermittent dopamine receptor activation results
in plastic alterations in gene expression and neuropeptide
formation within the striatal pathways,23 which subse-
quently lead to aberrant firing patterns of basal ganglia
output neurons. Taking the pathogenesis of LID into con-
sideration, age at PD onset, disease severity, and regimen
of chronic dopamine replacement therapy are obvious
risk factors for developing LID.24 Importantly, there is
increasing evidence that patients with PD with LID exhi-
bit an impaired plasticity within the larger motor net-
work4 (i.e., absent or poor plastic response in the primary
motor cortex [M1],5 erroneous cortico-striatal representa-
tions,25 impaired cerebello-cortical connections,26 and
abnormal inhibitory regulation in the cortico-cortical
connections27). Polymorphism of the brain-derived neu-
rotrophic factor gene, which regulates the synaptic plastic-
ity and efficacy in the cortex and striatum, has been also
reported to influence the time to develop LID.6 Several
studies have shown that neuromodulation of the aberrant
motor maps has potential therapeutic implications for
LID.26,27
Ample evidence has suggested that comorbid WMHs
could negatively influence the motor features8,10 and poor
levodopa response11,28 in PD. Likewise, patients in the
PD-WMH + group in this study showed more severe
motor deficits than those in the PD-WMH– group
despite the comparable striatal DAT availability between
the groups at an initial assessment. As a possible explana-
tion for the clinical impact of WMHs in PD, WM alter-
ations may interrupt the subcortical motor circuits,13
leading to more severe parkinsonian motor deficits.29 Fur-
thermore, WM lesions outside the frontal regions, where
major tracts linked to higher-order motor control are
located, also appear to disconnect the motor cortex from
the basal ganglia and cerebellum by either perilesional or
remote effects.14,15 Additionally, various pathologies
related to WMHs, including vascular pathology,30 low-
grade inflammation,31 Wallerian degeneration,32 and axo-
nal transport disruption,33 may facilitate the neurodegen-
erative process in patients with PD with a greater extra-
nigral pathological burden.34 In the present study, we
provide evidence for the first time that a severe WMH
burden was associated with the early development of LID,
even after adjusting for confounding factors such as LED
and nigrostriatal dopamine depletion. Accordingly, based
on previous and current studies, the WMH burden seems
to be an important clinical parameter, acting as a predic-
tor of parkinsonian motor outcome, as well as LID devel-
opment in patients with PD.
In this study, the risk of developing LID did not differ
according to the regional WMH distribution. Indeed, sev-
eral previous studies have emphasized the frontal area,
which is structurally and functionally interconnected to
the striatum, as the core neural correlates of LID. In neu-
roimaging studies, Cerasa and colleagues have consistently
reported that the right inferior frontal cortex would play
a key role in the pathophysiology of LID, with an increase
Table 4. The predictive accuracy of the Cox regression models
according to white matter hyperintensities of each brain region.
AIC Linear trend v 2 Harrell’s C iAUC
Total WMH 1021.305 23.85 0.655 0.636
Periventricular
WMH
1027.626 17.59 0.647 0.617
Lobar WMH 1021.858 23.35 0.655 0.634
Frontal WMH 1024.405 20.98 0.645 0.601
Parietal WMH 1022.108 22.69 0.656 0.635
Temporal WMH 1026.333 18.91 0.633 0.620
Occipital WMH 1023.419 21.40 0.643 0.628
Basal ganglia
WMH
1025.168 19.94 0.637 0.622
Infratentorial
WMH
1027.006 18.25 0.631 0.617
The Akaike information criterion (AIC) was calculated for each Cox
regression model to demonstrate which regional WMHs is more
explanatory and informative in predicting the development of LID (a
smaller AIC indicates the preferred model). Additionally, discriminatory
ability (linear trend v2 test), the concordance index (Harrell’s C-index),
and a global concordance probability (integrated area under the curve
[iAUC]) were also calculated for each Cox regression model to assess
the predictive accuracy (larger discriminatory ability, Harrell’s C-index,
and iAUC indicate better predictive ability). There were no significant
differences in iAUC between the Cox regression models, which were
calculated using a bootstrapping method with resampling 1000 times,
suggesting that the predictive accuracy of each Cox regression model
was comparable.
ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 235
S. J. Chung et al. WMH and LID in PD
in gray matter volume or thickness35,36 and an abnormal
pattern of functional connectivity in this region.27,37
Recently, we found an association between the develop-
ment of LID and frontal lobe-based cognitive decline,38
suggesting that abnormal striatal and cortical plasticity in
the frontal area might result in both aberrant motor and
cognitive loops. In this study, the lack of regional pre-
dominance in the impact of WMHs on LID development
might be due to a strong correlation between the WMH
rating scores in each brain region. In particular, WMH
rating scores of the frontal lobe were well correlated with
those of the other lobes (parietal lobe, c = 0.754; tempo-
ral lobe, c = 0.654; occipital lobe, c = 0.577) with a suffi-
ciently large effect size. The total WMH severity was also
well correlated with the subregional WMH severity
(periventricular, c = 0.836; lobar, c = 0.717), suggesting
that the pathological burden related to WMHs would
affect the entire brain without region-specific predomi-
nant patterns. Additionally, the remote effects of WM
lesions14,15 might make it possible to interrupt the sub-
cortical motor circuits even if the frontal area was not
involved. Further studies using diffusion tensor imaging,
which can detect microstructural WM alterations (e.g.,
structural WM connectivity) early,39 would provide more
answers with respect to the conclusions of this study.
Our study has some limitations. First, the age at PD
onset and baseline motor severity, which are important
risk factors for developing LID,24 differed between the PD
groups. However, consistent results were obtained from
the sensitivity analyses using the propensity score-
matched samples. Furthermore, the PD-WMH + group
had a higher risk of developing LID despite their older
age at PD onset. Individual variability in the regimens of
dopamine replacement therapy may also affect the devel-
opment of LID,40 although the LED per body weight at
LID onset or last visit was included as a covariate in the
Cox regression model. Second, the severity of WMHs was
not quantified as the WMH volume but rather visually
assessed based on the CREDOS ischemia classification
system17 and the Scheltens scale.20 However, these visual
rating scales are known to correlate well with the auto-
matically measured WMH volume.17 Third, the burden of
vascular risk factors, which might affect the progression
of WMHs, could have variably changed during follow-up;
however, this confounding effect is difficult to assess in a
retrospective study design. Finally, minimal to mild LID
may not be detected owing to our determination of the
presence of LID via medical records. In addition, there is
a lack of detailed information on the adverse effects of
LID development on quality of life.
In conclusion, this study demonstrates that the burden
of WMHs is associated with the occurrence of LID in
patients with PD. These findings suggest that comorbid
WMHs may affect the subcortical motor pathways, lead-
ing to an increased risk of developing LID.
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